Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05135910
Other study ID # HSG-201
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date January 13, 2022
Est. completion date September 30, 2024

Study information

Verified date August 2023
Source Hallux, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The key objective is to establish the efficacy, safety, tolerability, and pharmacokinetics of investigational drug Hallux Terbinafine Subungual Gel (HSG) administered over 44 weeks to patients with distal-lateral subungual onychomycosis (DLSO).


Description:

Primary Efficacy: To identify patients achieving Complete Cure in the target toenail at Week 52. Secondary Efficacy: To identify patients that have achieved 1) Clinical Cure, 2) Mycological Cure, and/or 3) Positive Response in the target toenail at Week 52. Plasma Pharmacokinetics: To characterize concentrations of terbinafine and major metabolite in a subpopulation of patients over the study period. Nail Pharmacokinetics: To characterize concentrations of terbinafine and major metabolite in distal nail clippings in patients over the study period. HSG Safety and Tolerability Profile: To establish from plasma pharmacokinetics, related adverse events, treatment site reactions, pain, clinically significant changes in medical condition and/or medications, and clinically significant changes in liver function, serum chemistry, urinalysis, and complete blood count over the study period. Subungual Topical Procedure: To establish the ease and durability of once monthly and once bi-monthly HSG subungual topical treatments, the Investigator will record at selected time points 1) nail measurements indicating progressive clearing, 2) the ease and depth of each topical administration, 3) the investigational drug volume administered each treatment, and 4) patient tolerability.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 35
Est. completion date September 30, 2024
Est. primary completion date September 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Male and females 18 - 75 years of age inclusive - Patients with DLSO of at least one great toe - Patients with DLSO in the target toe confirmed by positive KOH and positive fungal culture for dermatophytes - Willingness to abstain from pedicures, nail clipping, or application of nail polish or nail cosmetics to their toenails over the study period Exclusion Criteria: - History of any significant chronic fungal disease other than onychomycosis or an immunocompromised condition - Any previous surgery to or abnormalities of the target toe that in the investigator's opinion could prevent the toenail surface area from clearing even if eradication of the DLSO infection is achieved - Participation in another clinical study of an investigational drug or device within 3 months of screening - No administration of oral terbinafine or another oral antifungal within 6 months of screening - No topical antifungal used for onychomycosis or a dermatophyte infection (i.e. tinea pedis) within 3 months of screening - No uncontrolled diabetes mellitus - No severe psoriasis or severe atopic dermatitis Other protocol-defined inclusion/exclusion criteria may apply

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Hallux Terbinafine Subungual Gel
Hallux Terbinafine Subungual Gel (HSG) administered every 1 to 2 months over 44 weeks.

Locations

Country Name City State
United States J&S Studies College Station Texas
United States OrthoArizona - East Valley Foot & Ankle Specialists Mesa Arizona
United States Front Range Foot and Ankle Clinic Parker Colorado
United States Oregon Dermatology & Research Center Portland Oregon

Sponsors (1)

Lead Sponsor Collaborator
Hallux, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Plasma Pharmacokinetics To characterize plasma concentrations of terbinafine and metabolite from a subset of patients over the study period Week 52
Other Nail Pharmacokinetics To characterize nail concentrations of terbinafine and metabolite from patients over the study period Week 52
Other Subungual Topical Procedure To evaluate the ease and durability of once monthly and once bi-monthly HSG subungual topical treatments to the target toe over 44 weeks. Nail measurements indicating progressive clearing are recorded from an Investigator Global Assessment scale referencing % disease involvement corroborated by nail image analysis. The ease and durability of subungual topical treatment is established using a 5-point Likert Scale. Patient local tolerability is established using a Treatment Site Assessment Scale and Pain Intensity Scale. Week 44
Other Patient Global Assessment To establish each patient's impression of DLSO improvement in their target toe over the study period, patients will reference the following scale (0 = clear of DLSO, 1 = marked improvement of DLSO, 2 = moderately improved DLSO, 3 = slightly improved DLSO, 4 = unchanged, 5 = worse) Week 52
Other Safety and Tolerability: Established from patient incidence of Treatment-Emergent Adverse Events Indicated by the number of patients with treatment-related adverse events assessed by Common Terminology Criteria for Adverse Events (CTCAE) Monitored from screening visit to end of study visit (Week 52)
Other Safety and Tolerability: Established from clinical laboratory results Indicated by clinically significant changes in patient liver function, serum chemistry, urinalysis, and complete blood count over the study period Monitored at selected time points from screening visit to end of study visit (Week 52)
Other Safety and Tolerability: Established from patient reported medical condition and use of medications Monitored by assessing clinically significant changes in patient medical condition and/or use of medications over the study period Monitored from screening visit to end of study visit (Week 52)
Primary Complete Cure at Week 52 in the Target Toe Complete Cure is defined as 1) 100% healthy, clear nail, and 2) negative mycology. Healthy, clear nail is absent any disease involvement attributable to DLSO and is determined by Investigator Global Assessment (IGA). Negative mycology is defined as zero visualization of septate hyphae by KOH microscopy (negative KOH) combined with a fungal culture negative for causal dermatophytes (negative fungal culture). Week 52
Secondary Clinical Cure in the Target Toe 100% healthy, clear nail Week 52
Secondary Mycological Cure in the Target Toe Negative KOH, negative fungal culture Week 52
Secondary Positive Response in the Target Toe = 80% decrease in disease involvement Week 52
See also
  Status Clinical Trial Phase
Completed NCT03110029 - Evaluating the Efficacy and Compatibility of Efinaconazole 10% Solution (Jublia) for the Treatment of Toenail Onychomycosis in Patients Wearing Toenail Polish Compared to Those Without Polish Phase 4
Active, not recruiting NCT05110638 - Safety and Tolerability Study of SKX-16 in Subjects With Moderate to Severe Distal Subungual Onychomycosis Phase 1
Completed NCT05260450 - Laser Treatment of Toenail Onychomycosis With a 1064 nm Nd:YAG-laser N/A
Completed NCT03382717 - Efficacy and Safety of a Medical Device for the Treatment of Toenail Onychomycosis N/A
Not yet recruiting NCT06417983 - Topical Application of Essential Oils to Treat Onchomycosis
Withdrawn NCT03094468 - Study to Evaluate the Efficacy and Safety of P-3058 Nail Solution in the Treatment of Onychomycosis Phase 3
Recruiting NCT05674747 - Pilot Study of Swift Microwave Device for Onychomycosis Phase 1/Phase 2
Recruiting NCT06006455 - Effect of the Erchonia® LunulaLaserâ„¢ for the Treatment of Toenail Onychomycosis N/A
Not yet recruiting NCT03098342 - Comparison of Efficacy and Safety Between Methylene Blue-mediated Photodynamic Therapy and 5% Amorolfine Nail Lacquer for Toenail Onychomycosis Treatment N/A
Completed NCT03216200 - Early Feasibility Study to Evaluate the Efficacy of the RenewalNailâ„¢ Plasma Treatment System in Patients With Onychomycosis (Fungal Nail) N/A
Recruiting NCT04042857 - Safety and Efficacy of Next Science Gel on Toenail Fungus N/A
Active, not recruiting NCT05139888 - Light Therapy for Onychomycosis Study N/A
Completed NCT04961684 - Clinical Evaluation of Efficacy and Safety of a Medical Device for the Treatment of Toenail Onychomycosis N/A
Completed NCT03141840 - Clinical Trial of Topical ABL01 Treatment of Onychomycosis N/A
Recruiting NCT04084782 - An Internet Mediated Research Study to Assess the Quality of Life of Consumers With Self-reported Fungal Nail Infection (Onychomycosis) During Treatment With Scholl Fungal Nail.
Withdrawn NCT03066336 - A Study to See if Low Level Laser Light Can Help to Treat Toenail Fungus N/A